GetTopicDetailResponse(id=cc81e30066, topicName=FDA咨詢小組, introduction=FDA咨詢小組, content=null, image=null, comments=3, allHits=1025, url=https://h5.medsci.cn/topic?id=7300, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98907, tagList=[TagDto(tagId=98907, tagName=FDA咨詢小組)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2036950, encodeId=03132036950e9, content=<a href='/topic/show?id=cc81e30066' target=_blank style='color:#2F92EE;'>#FDA咨詢小組#</a>, objectTitle=FDA咨詢小組支持默克公司的口服COVID-19藥物，但無法確定是否對Omicron變種有效, objectType=article, longId=221434, objectId=a66d221434cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d221434cd, replyNumber=0, likeNumber=73, createdTime=2022-02-06, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d221434cd, moduleTitle=FDA咨詢小組支持默克公司的口服COVID-19藥物，但無法確定是否對Omicron變種有效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a66d221434cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036949, encodeId=626720369490d, content=<a href='/topic/show?id=cc81e30066' target=_blank style='color:#2F92EE;'>#FDA咨詢小組#</a>, objectTitle=靶向BCMA的ADC藥物belantamab mafodotin，獲得FDA咨詢小組支持治療復(fù)發(fā)或難治的多發(fā)性骨髓瘤患者, objectType=article, longId=197577, objectId=fa9619e5777b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9619e5777b, replyNumber=0, likeNumber=89, createdTime=2020-08-22, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9619e5777b, moduleTitle=靶向BCMA的ADC藥物belantamab mafodotin，獲得FDA咨詢小組支持治療復(fù)發(fā)或難治的多發(fā)性骨髓瘤患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fa9619e5777b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036948, encodeId=4dbc2036948e3, content=<a href='/topic/show?id=cc81e30066' target=_blank style='color:#2F92EE;'>#FDA咨詢小組#</a>, objectTitle=FDA咨詢小組就是否批準(zhǔn)Durect公司的Posimir用于手術(shù)后鎮(zhèn)痛產(chǎn)生了分歧, objectType=article, longId=186513, objectId=b16118651367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b16118651367, replyNumber=0, likeNumber=97, createdTime=2020-03-31, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b16118651367, moduleTitle=FDA咨詢小組就是否批準(zhǔn)Durect公司的Posimir用于手術(shù)后鎮(zhèn)痛產(chǎn)生了分歧, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b16118651367)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
